| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11344520 | IBSA INST BIO | Effects of heparin on topical use of plasters containing a non-steroidal anti-inflammatory drug |
Feb, 2035
(10 years from now) | |
| US11351133 | IBSA INST BIO | Effects of heparin on topical use of plasters containing a non-steroidal anti-inflammatory drug |
Feb, 2035
(10 years from now) | |
Licart is owned by Ibsa Inst Bio.
Licart contains Diclofenac Epolamine.
Licart has a total of 2 drug patents out of which 0 drug patents have expired.
Licart was authorised for market use on 19 December, 2018.
Licart is available in system;topical dosage forms.
Licart can be used as method of treating acute pain due to minor strains, sprains, and contusions using a diclofenac patch containing heparin for once daily administration where heparin is not released.
The generics of Licart are possible to be released after 20 February, 2035.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 19, 2021 |
Drugs and Companies using DICLOFENAC EPOLAMINE ingredient
Market Authorisation Date: 19 December, 2018
Treatment: Method of treating acute pain due to minor strains, sprains, and contusions using a diclofenac patch containing heparin for once daily administration where heparin is not released
Dosage: SYSTEM;TOPICAL
LICART family patents
